Open Orphan receives Court approval for the reduction of capital

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and a world leader in vaccine and antiviral testing using human challenge clinical trials, has confirmed that, following its announcement on 13 April 2021, it has received Court approval for the reduction in capital. The reduction of capital will become effective on registration of the Court order at Companies House, which is expected to occur in the next few days.

The reduction of capital will give the Company the ability to not only effect the Distribution in Specie, as part of the proposed spin-out of certain non-core Development IP Assets, but also to make other distributions to Shareholders and/or buy back its own Open Orphan Ordinary Shares in the future if and when the Directors may consider that it is appropriate to do so.

As previously announced, the Board has decided that a spin-out and admission to AIM of the wholly owned Development IP Assets may provide the opportunity to secure separate financial resources for the Development IP Assets, with the goal of enabling accelerated development of the asset portfolio and achievement of development and commercial milestones. The Development IP Assets include HVO-001, an orally available, small molecule immunomodulator drug with potential as a treatment for severe influenza and symptoms requiring treatment in hospital with the drug unaffected by viral heterogeneity. It has the potential to treat a broad range of serious unmet needs in patients suffering from severe and fatal respiratory disease.

It is anticipated that a spin-out pursuant to the Demerger would allow the Company’s shareholders to benefit from both the value of the Development IP Assets and the standalone value of the remaining business as it progresses through its own key milestones.

The Company continues to make good progress towards delivering against the potential Demerger and Distribution in Specie and will update shareholders in due course.

Terms defined in the Company’s circular dated 13 April 2021 shall have the same meanings in the announcement.

Cathal Friel, Executive Chairman of Open Orphan plc commented: “We are delighted to have received Court approval of the reduction of capital. The reduction of capital will allow us to return value to shareholders as we go forward either as a distribution in specie as part of the proposed spin-off or through a share buy back or a payment of a dividend, as appropriate. The Company and the entire Open Orphan team have made significant progress in the past year and we remain on target with all of our plans as we continue to build the company going forward.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

CMC regulatory team capabilities

For 20+ years, members of the CMC regulatory team supported several (bio)pharmaceutical companies to ensure manufacture of safe, effective, and high-quality drug products for patients globally. The support includes: Independent, trusted advice on your regulatory activities

Open Orphan Plc

How to build up your child’s immune system

Our Top 7 Tips to Boots Your Child’s Immune System Protecting your children from germs, bacteria and illnesses is a common concern for parents. Flu, colds, viruses and infections can cause misery for both you and

Open Orphan Plc

Open Orphan’s hVIVO presenting at the World Vaccine Congress

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a

Open Orphan Plc

Hay fever season is back with a vengeance

Hay Fever is back! As the most common form of non-infectious rhinitis, hay fever affects 10-30% of adults and up to 40% of children. Hay fever season typically starts in mid-March as trees bloom until May.

Open Orphan Plc

Open Orphan Investor Presentation March 2022 (Video)

Open Orphan plc (LON:ORPH) CEO Yamin ‘Mo’ Khan talks through its March 2022 Investor Presentation. Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and

Open Orphan Plc

Strategies for Non-clinical safety assessment of vaccines

Setting the scene Over the past century, vaccines have made a large impact on public health, as recently demonstrated by the treatment of the worldwide Covid-pandemic. Since, in general, vaccines are administered to healthy individuals, including

Open Orphan Plc

Open Orphan’s hVIVO signs €6m contract for respiratory study

Dublin-listed clinical trials group Open Orphan has announced that its subsidiary Hvivo has signed a £5 million (€6m) human challenge study contract with a European biotechnology company. The study will test the company’s intravenous antiviral candidate for respiratory syncytial virus,

Open Orphan Plc

Open Orphan opens two new testing facilities

Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment facility in Manchester. Open Orphan tests vaccines and antivirals using human

Open Orphan Plc

FluCamps’ UK Covid Challenge summary

FluCamps’ parent company hVIVO recently published results for the world’s first COVID-19 human challenge trial, World’s first COVID-19 Characterisation Study (investis.com), which ran in Spring of 2021. FluCamp recruited 36 volunteers for this trial under the title

Open Orphan Plc

Clinical PK and PD Service at Venn Breda

For more than 20 years, the clinical pharmacokinetic (PK: understanding the kinetics of a drug in terms of absorption, distribution, metabolism and elimination [ADME]) and pharmacodynamic (PD: the biochemical and physiological effects of a drug) team

Open Orphan Plc

Open Orphan names Khan as new CEO

Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin ‘Mo’ Khan as its chief executive with immediate effect. Mr Khan joined the company’s board as a non-executive director in October 2021 and has worked